Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Paxmedica Inc (NQ: PXMD ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, May 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Paxmedica Inc < Previous 1 2 3 4 Next > PaxMedica Inc. (NASDAQ: PXMD) Shares Corporate Update and Commitment to Advancing Therapies for Neurological Disorders, Prepares for Key Engagements with the FDA May 29, 2024 Via Investor Brand Network Study Discovers Elevated Risk of Toxicity Among Autistic Kids May 24, 2024 Via Investor Brand Network PaxMedica Inc. (NASDAQ: PXMD) Seeking to Qualify for Neglected Tropical Disease Priority Review Voucher Program in Wake of Malawi Major Sleeping Sickness Crisis May 24, 2024 Via Investor Brand Network BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Ensuring Access to Life-Saving Treatments May 22, 2024 Via Investor Brand Network Researcher Wants to Untangle Environmental, Genetic Complexities of Autism May 08, 2024 Via Investor Brand Network Rising Cases of Autism in UK Raise Concerns March 08, 2024 Via Investor Brand Network BioMedNewsBreaks — PaxMedica Inc. (PXMD) Appeals NASDAQ Delisting Decision, Prepares for June FDA Meeting May 15, 2024 Via Investor Brand Network Exposures Product Safety PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 May 15, 2024 From PaxMedica, Inc. Via GlobeNewswire BioMedNewsBreaks — PaxMedica Inc. (PXMD) Continues Advancement of PAX-101 Regulatory Strategy May 07, 2024 Via Investor Brand Network Exposures Product Safety PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy May 07, 2024 From PaxMedica, Inc. Via GlobeNewswire PaxMedica Inc. (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA May 01, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Featured in Latest Bell2Bell Podcast Release April 26, 2024 Via Investor Brand Network “Urgent Action: PaxMedica Inc. (NASDAQ: PXMD) Addresses Medical Crisis in Malawi” April 24, 2024 Via Investor Brand Network BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDA April 24, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Responds to Emergency Request for IV Suramin, Commits to Provide Immediate Access to PAX-101 April 23, 2024 Via Investor Brand Network PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 April 23, 2024 From PaxMedica, Inc. Via GlobeNewswire Misinformation on TikTok Causing Many to Misdiagnose Themselves as Autistic April 19, 2024 Via Investor Brand Network BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) in Process of Responding to Emergency Request for IV Suramin from African Health Ministry April 17, 2024 Via Investor Brand Network Exposures Product Safety PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness April 16, 2024 From PaxMedica, Inc. Via GlobeNewswire InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Announces ‘Milestone Achievement’ on Journey to Developing PAX-101 April 12, 2024 Via Investor Brand Network PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission April 11, 2024 From PaxMedica, Inc. Via GlobeNewswire BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Developing Robust Product Lineup to Address ASD, Associated Neurodevelopmental Conditions April 05, 2024 Via Investor Brand Network Prenatal Exposure to Caffeine and High-Fat Diets Heighten Autism Risk in Rodent Models April 01, 2024 Via Investor Brand Network PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium March 21, 2024 Via Investor Brand Network BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients March 20, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Shares Vision, Innovations in ASD Treatments in Updated Company Presentation March 13, 2024 Via Investor Brand Network PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments March 13, 2024 From PaxMedica, Inc. Via GlobeNewswire PaxMedica Inc. (NASDAQ: PXMD) Pursues Autism Treatment as Diagnostic App Shows Promise to Effective ASD Diagnosis March 08, 2024 Via Investor Brand Network BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Committed to Developing Groundbreaking Therapies, Transformative Solutions March 01, 2024 Via Investor Brand Network PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline of Products to Address Prevalence and Unmet Medical Needs of Autism Spectrum Disorder February 20, 2024 Via Investor Brand Network < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
